BioCentury
ARTICLE | Politics, Policy & Law

BIO seeks clarity, transparency on IRA small biotech exemption

Neurocrine and Incyte have said they could qualify for the three-year exemption from price-setting

May 26, 2023 8:48 PM UTC

BIO is calling on CMS to provide more clarity and predictability about its plans for implementing provisions in the IRA that give some small biotechs a temporary exemption from Medicare drug price negotiation.

The Small Biotech Exemption is intended to prevent the Inflation Reduction Act from having devastating effects on companies that live or die on sales to Medicare from a single product. ...